Click to Enlarge

Chromatin Deregulation in Cancer


Subject Area(s):  Human Biology and DiseaseCancer Biology

Edited by Scott Armstrong, Dana-Farber Cancer Institute; Steve Henikoff, Fred Hutchinson Cancer Research Center; Chris Vakoc, Cold Spring Harbor Laboratory

Download a Free Excerpt from Chromatin Deregulation in Cancer:

Preface
Index


© 2017 • 382 pages, illustrated (54 color, 10 B&W), index
Hardcover • $135 94.50
ISBN  978-1-621821-40-3
You save: 30%
You will receive free shipping on this item at checkout.
Free shipping offer applies to direct website purchases by individual U.S. and Canada customers only.

Print Book + eBook
    Best value!
$210 $121.50 Add To Cart
Print Book$135 $94.50 Add To Cart
eBook$75 $60.00 Add To Cart

Bulk discounts available for your lab or class. Click here to inquire.

eBooks use Adobe Digital Editions software. Click here for more information.

  •     Description    
  •     Contents    

Description

The human genome is packaged into chromatin, which is composed of numerous proteins that help control gene expression, DNA replication and repair, and genome stability. In recent years, it has become clear that the deregulation of chromatin structure plays an important role in numerous cancers.

Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine examines the chromatin components that are commonly mutated, what is understood about the mechanisms that lead to hematological malignancies and solid tumors, and prospects for the therapeutic modulation of chromatin. The contributors describe how histone proteins, histone-modifying enzymes, chromatin remodelers, transcriptional regulatory complexes, enhancer-associated factors, and signaling proteins are dysregulated in cancer pathogenesis. In addition, the roles of DNA methylation and noncoding RNAs are covered.

The authors also discuss small molecules and other drugs that are currently under development or already used to treat cancer (e.g., HDAC inhibitors and DNA hypomethylating agents). This book is therefore essential reading for all cancer biologists, cell and molecular biologists, and pharmacologists interested in understanding cancer therapies.

Contents

Preface
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer
Anne Laugesen, Jonas Westergaard Højfeldt, and Kristian Helin
The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer
Richard L. Bennett, Alok Swaroop, Catalina Troche, and Jonathan D. Licht
Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia
Andrei V. Krivtsov, Takayuki Hoshii, and Scott A. Armstrong
Oncogenic Mechanisms of Histone H3 Mutations
Daniel N. Weinberg, C. David Allis, and Chao Lu
MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer
Christie C. Sze and Ali Shilatifard
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
Courtney Hodges, Jacob G. Kirkland, and Gerald R. Crabtree
DNMT3A in Leukemia
Lorenzo Brunetti, Michael C. Gundry, and Margaret A. Goodell
TET2 in Normal and Malignant Hematopoiesis
Robert L. Bowman and Ross L. Levine
Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer
Narsis Attar and Siavash K. Kurdistani
The Role of Additional Sex Combs-Like Proteins in Cancer
Jean-Baptiste Micol and Omar Abdel-Wahab
SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation
Catherine C. Fahey and Ian J. Davis
ATRX and DAXX: Mechanisms and Mutations
Michael A. Dyer, Zulekha A. Qadeer, David Valle-Garcia, and Emily Bernstein
The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer
Alea A. Mills
Cohesin Mutations in Cancer
Magali De Koninck and Ana Losada
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li and Edward Seto
DNA Hypomethylating Drugs in Cancer Therapy
Takahiro Sato, Jean-Pierre J. Issa, and Patricia Kropf
Targeting Cancer Cells with BET Bromodomain Inhibitors
Yali Xu and Christopher R. Vakoc
Histone Lysine Demethylase Inhibitors
Ashwini Jambhekar, Jamie N. Anastas, and Yang Shi
Mechanisms of Nucleosome Dynamics In Vivo
Steven Henikoff
Nonhistone Lysine Methylation in the Regulation of Cancer Pathways
Scott M. Carlson and Or Gozani
Long Noncoding RNAs: At the Intersection of Cancer and Chromatin Biology
Adam M. Schmitt and Howard Y. Chang
Index